Brenntag Specialties Acquires MCE Pharma
Brenntag recently announced the acquisition of MCE Pharma. The acquisition and additional investments in the site of MCE Pharma will strengthen Brenntag’s capabilities across the entire pharmaceutical and biopharmaceutical value chain.
The existing state-of-the-art GMP facilities, advanced sampling services, and expertise in both OTC product development and GMP powder pack-off will add to the growing portfolio of capabilities and value-added services Brenntag Pharma offers principals and customers in the EMEA region.
“The integration of GMP blending and down-packing, along with added warehouse and office space, positions us to meet growing demand while ensuring operational excellence. It’s a powerful enhancement to our portfolio that reinforces our commitment to quality, speed, and customer-centric solutions” said Joakim Rehné, President Pharma EMEA at Brenntag.
Ivan Mikes, Member of the Administration Board of MCE Pharma, added: “After growing our portfolio and expertise in development, production, and warehousing for distribution of specialty chemicals and services, we are excited to expand our reach and customer base significantly by joining Brenntag. Our team will get the chance to leverage their expertise and serve the entire EMEA region together with the Brenntag Pharma colleagues.”
Gust Desmedt, Global President Pharma at Brenntag Specialties, noted: “This acquisition represents a key milestone in our strategic initiatives to further expand our biopharmaceutical services on top of our offering in traditional small molecules. With the added capabilities MCE Pharma offers, we are confident we can serve additional customers with value-added services and serve the needs of our supply partners in the rapid growing Biopharma market in EMEA and globally with specialized biobuffers.”
Financial details of the deal are not being disclosed. Signing and closing of the transaction occurred simultaneously.
